Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis

MLA

Maxim Grymonprez, et al. “Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: A Systematic Review and Meta-Analysis.” Cardiovascular Drugs and Therapy, vol. 36, Jan. 2021, pp. 749–61. EBSCOhost, https://doi.org/10.1007/s10557-020-07122-6.

APA

Maxim Grymonprez, Tine De Backer, Stephane Steurbaut, Koen Boussery, & Lies Lahousse. (2021). Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 36, 749–761. https://doi.org/10.1007/s10557-020-07122-6

Chicago

Maxim Grymonprez, Tine De Backer, Stephane Steurbaut, Koen Boussery, and Lies Lahousse. 2021. “Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: A Systematic Review and Meta-Analysis.” Cardiovascular Drugs and Therapy 36 (January): 749–61. doi:10.1007/s10557-020-07122-6.